This page provides comprehensive experimental methodology for quantifying mitochondria-lysosome contact site (MLCS) abnormalities in patient-derived neurons and testing therapeutic rescue strategies. These protocols are designed for iPSC-derived dopaminergic neurons from Parkinson's disease patients and healthy controls. Mitochondria-lysosome contact sites represent a critical intersection of mitochondrial quality control and lysosomal function, both of which are profoundly disrupted in Parkinson's disease pathogenesis. [1]
Mitochondria-lysosome contact sites (MLCS) are dynamic membrane junctions where mitochondria and lysosomes physically interact to facilitate material transfer and metabolic exchange. These contacts serve multiple essential cellular functions including mitochondrial fission, lysosomal trafficking, lipid exchange, and mitophagy. [2]
In Parkinson's disease, MLCS are disrupted by mutations in genes including LRRK2, GBA1, SNCA, and PARK2 (parkin), leading to impaired mitochondrial quality control and lysosomal dysfunction. [3]
The disruption of MLCS contributes to PD through several mechanisms: [4]
| Genetic Background | Mutation | Clinical Relevance |
|---|---|---|
| LRRK2 | G2019S | Most common genetic cause of PD, affects lysosomal function |
| GBA | N370S | High penetrance, severe lysosomal dysfunction |
| SNCA | A53T | Alpha-synuclein multiplication, affects mitochondrial dynamics |
| PARK2 | null | Autosomal recessive juvenile PD, parkin deficiency |
| PINK1 | kinase domain | Mitophagy impairment, early-onset PD |
| Healthy Controls | None | Age-matched baselines |
Protocols for differentiating induced pluripotent stem cells (iPSCs) into midbrain dopaminergic neurons typically require 25-35 days of differentiation, following modifications of established protocols. Neurons should be characterized by expression of tyrosine hydroxylase (TH), FOXA2, and LMX1A. Quality control measures include:
Alternative dyes for orthogonal validation:
| Protein | Function | Detection Method |
|---|---|---|
| VAPB | ER-mitochondria tether, MLCS regulation | Western blot, immunofluorescence |
| PTPIP51 | Mitochondrial outer membrane tether | Western blot, immunofluorescence |
| Rab7 | Lysosomal trafficking | Western blot, immunofluorescence |
| Parkin | Ubiquitin ligase, MLCS stabilization | Western blot, immunofluorescence |
| PINK1 | Kinase, mitophagy initiation | Western blot, immunofluorescence |
| Compound | Target | Expected Effect |
|---|---|---|
| Rapamycin | mTOR | Enhanced mitophagy, increased MLCS |
| Genistein | Tyrosine kinases | VAPB phosphorylation |
| Nicotinamide | Sirtuins | Mitochondrial biogenesis |
| Urolithin A | Mitophagy | Mitochondrial function improvement |
Matsuda et al. PINK1/parkin mitophagy pathway (2020). 2020. ↩︎
Sarkar et al. Rapamycin and autophagy in neurodegeneration (2020). 2020. ↩︎
Gonzalez et al. Urolithin A and mitophagy (2022). 2022. ↩︎
Borsche et al. Novel strategies targeting mitochondria-lysosome contact sites for the treatment of neurological diseases (2024). 2024. ↩︎